Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Detecting fluoxetine and norfluoxetine in wild bird tissues and feathers.

Whitlock SE, Pereira MG, Lane J, Sleep D, Shore RF, Arnold KE.

Environ Int. 2019 May;126:193-201. doi: 10.1016/j.envint.2019.01.083. Epub 2019 Feb 22.

2.

Cross-scale effects of spruce budworm outbreaks on boreal warblers in eastern Canada.

Drever MC, Smith AC, Venier LA, Sleep DJH, MacLean DA.

Ecol Evol. 2018 Jun 27;8(15):7334-7345. doi: 10.1002/ece3.4244. eCollection 2018 Aug.

3.

Long-term increase in secondary exposure to anticoagulant rodenticides in European polecats Mustela putorius in Great Britain.

Sainsbury KA, Shore RF, Schofield H, Croose E, Pereira MG, Sleep D, Kitchener AC, Hantke G, McDonald RA.

Environ Pollut. 2018 May;236:689-698. doi: 10.1016/j.envpol.2018.02.004.

PMID:
29438955
4.

Neonicotinoid residues in UK honey despite European Union moratorium.

Woodcock BA, Ridding L, Freeman SN, Pereira MG, Sleep D, Redhead J, Aston D, Carreck NL, Shore RF, Bullock JM, Heard MS, Pywell RF.

PLoS One. 2018 Jan 3;13(1):e0189681. doi: 10.1371/journal.pone.0189681. eCollection 2018.

5.

Country-specific effects of neonicotinoid pesticides on honey bees and wild bees.

Woodcock BA, Bullock JM, Shore RF, Heard MS, Pereira MG, Redhead J, Ridding L, Dean H, Sleep D, Henrys P, Peyton J, Hulmes S, Hulmes L, Sárospataki M, Saure C, Edwards M, Genersch E, Knäbe S, Pywell RF.

Science. 2017 Jun 30;356(6345):1393-1395. doi: 10.1126/science.aaa1190.

PMID:
28663502
6.

Engineered Polymer-Transferrin Conjugates as Self-Assembling Targeted Drug Delivery Systems.

Makwana H, Mastrotto F, Magnusson JP, Sleep D, Hay J, Nicholls KJ, Allen S, Alexander C.

Biomacromolecules. 2017 May 8;18(5):1532-1543. doi: 10.1021/acs.biomac.7b00101. Epub 2017 Apr 11.

PMID:
28350442
7.

Constitutive changes in pigment concentrations: implications for estimating isoprene emissions using the photochemical reflectance index.

Harris A, Owen SM, Sleep D, Pereira MDGDS.

Physiol Plant. 2016 Feb;156(2):190-200. doi: 10.1111/ppl.12361. Epub 2015 Sep 23.

PMID:
26249646
8.

Albumin and its application in drug delivery.

Sleep D.

Expert Opin Drug Deliv. 2015 May;12(5):793-812. doi: 10.1517/17425247.2015.993313. Epub 2014 Dec 18. Review.

PMID:
25518870
9.

Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies.

Sand KM, Dalhus B, Christianson GJ, Bern M, Foss S, Cameron J, Sleep D, Bjørås M, Roopenian DC, Sandlie I, Andersen JT.

J Biol Chem. 2014 Jun 13;289(24):17228-39. doi: 10.1074/jbc.M113.522565. Epub 2014 Apr 24.

10.

Phosphorus retention and remobilization along hydrological pathways in karst terrain.

Jarvie HP, Sharpley AN, Brahana V, Simmons T, Price A, Neal C, Lawlor AJ, Sleep D, Thacker S, Haggard BE.

Environ Sci Technol. 2014 May 6;48(9):4860-8. doi: 10.1021/es405585b. Epub 2014 Apr 10.

PMID:
24720609
11.

Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding.

Andersen JT, Dalhus B, Viuff D, Ravn BT, Gunnarsen KS, Plumridge A, Bunting K, Antunes F, Williamson R, Athwal S, Allan E, Evans L, Bjørås M, Kjærulff S, Sleep D, Sandlie I, Cameron J.

J Biol Chem. 2014 May 9;289(19):13492-502. doi: 10.1074/jbc.M114.549832. Epub 2014 Mar 20.

12.

Lake responses following lanthanum-modified bentonite clay (Phoslock®) application: an analysis of water column lanthanum data from 16 case study lakes.

Spears BM, Lürling M, Yasseri S, Castro-Castellon AT, Gibbs M, Meis S, McDonald C, McIntosh J, Sleep D, Van Oosterhout F.

Water Res. 2013 Oct 1;47(15):5930-42. doi: 10.1016/j.watres.2013.07.016. Epub 2013 Jul 23.

PMID:
23911225
13.

Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics.

Andersen JT, Cameron J, Plumridge A, Evans L, Sleep D, Sandlie I.

J Biol Chem. 2013 Aug 16;288(33):24277-85. doi: 10.1074/jbc.M113.463000. Epub 2013 Jul 1.

14.

Albumin as a versatile platform for drug half-life extension.

Sleep D, Cameron J, Evans LR.

Biochim Biophys Acta. 2013 Dec;1830(12):5526-34. doi: 10.1016/j.bbagen.2013.04.023. Epub 2013 Apr 29. Review.

PMID:
23639804
15.

High-frequency water quality time series in precipitation and streamflow: from fragmentary signals to scientific challenge.

Neal C, Reynolds B, Rowland P, Norris D, Kirchner JW, Neal M, Sleep D, Lawlor A, Woods C, Thacker S, Guyatt H, Vincent C, Hockenhull K, Wickham H, Harman S, Armstrong L.

Sci Total Environ. 2012 Sep 15;434:3-12. doi: 10.1016/j.scitotenv.2011.10.072. Epub 2012 Jan 14.

PMID:
22245159
16.

A molecular mechanism for modulating plasma Zn speciation by fatty acids.

Lu J, Stewart AJ, Sleep D, Sadler PJ, Pinheiro TJ, Blindauer CA.

J Am Chem Soc. 2012 Jan 25;134(3):1454-7. doi: 10.1021/ja210496n. Epub 2012 Jan 12.

17.

Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor.

Andersen JT, Dalhus B, Cameron J, Daba MB, Plumridge A, Evans L, Brennan SO, Gunnarsen KS, Bjørås M, Sleep D, Sandlie I.

Nat Commun. 2012 Jan 3;3:610. doi: 10.1038/ncomms1607.

18.

Manganese in the upper Severn mid-Wales.

Rowland AP, Neal C, Reynolds B, Neal M, Lawlor AJ, Sleep D.

J Environ Monit. 2012 Jan;14(1):155-64. doi: 10.1039/c1em10651a. Epub 2011 Nov 30.

PMID:
22130567
19.

The T cell receptor triggering apparatus is composed of monovalent or monomeric proteins.

James JR, McColl J, Oliveira MI, Dunne PD, Huang E, Jansson A, Nilsson P, Sleep DL, Gonçalves CM, Morgan SH, Felce JH, Mahen R, Fernandes RA, Carmo AM, Klenerman D, Davis SJ.

J Biol Chem. 2011 Sep 16;286(37):31993-2001. doi: 10.1074/jbc.M111.219212. Epub 2011 Jul 13.

20.

Aluminium in UK rivers: a need for integrated research related to kinetic factors, colloidal transport, carbon and habitat.

Neal C, Rowland P, Neal M, Jarvie HP, Lawlor A, Sleep D, Scholefield P.

J Environ Monit. 2011 Aug;13(8):2153-64. doi: 10.1039/c1em10362h. Epub 2011 Jun 23.

PMID:
21701704
21.

Determination of carbon-14 in environmental level, solid reference materials.

Blowers P, Caborn J, Dell T, Gingell T, Harms A, Long S, Sleep D, Stewart C, Walker J, Warwick PE.

Appl Radiat Isot. 2011 Oct;69(10):1323-9. doi: 10.1016/j.apradiso.2011.01.011. Epub 2011 Feb 2.

PMID:
21696972
22.

The biogeochemistry of arsenic in a remote UK upland site: trends in rainfall and runoff, and comparisons with urban rivers.

Rowland AP, Neal C, Reynolds B, Jarvie HP, Sleep D, Lawlor AJ, Neal M.

J Environ Monit. 2011 May;13(5):1255-63. doi: 10.1039/c0em00772b. Epub 2011 Mar 25.

PMID:
21442109
23.

Titanium in UK rural, agricultural and urban/industrial rivers: geogenic and anthropogenic colloidal/sub-colloidal sources and the significance of within-river retention.

Neal C, Jarvie H, Rowland P, Lawler A, Sleep D, Scholefield P.

Sci Total Environ. 2011 Apr 15;409(10):1843-53. doi: 10.1016/j.scitotenv.2010.12.021. Epub 2011 Feb 24.

PMID:
21353288
24.

The Ribble/Wyre observatory: major, minor and trace elements in rivers draining from rural headwaters to the heartlands of the NW England historic industrial base.

Neal C, Rowland P, Scholefield P, Vincent C, Woods C, Sleep D.

Sci Total Environ. 2011 Mar 15;409(8):1516-29. doi: 10.1016/j.scitotenv.2011.01.018. Epub 2011 Feb 5.

PMID:
21296383
25.

Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.

Goldberg AC, Bittner V, Pepine CJ, Kelly MT, Thakker K, Setze CM, Lele A, Sleep DJ.

Am J Cardiol. 2011 Mar 15;107(6):898-905. doi: 10.1016/j.amjcard.2010.11.009. Epub 2011 Jan 19.

PMID:
21247520
26.

Generation of priority research questions to inform conservation policy and management at a national level.

Rudd MA, Beazley KF, Cooke SJ, Fleishman E, Lane DE, Mascia MB, Roth R, Tabor G, Bakker JA, Bellefontaine T, Berteaux D, Cantin B, Chaulk KG, Cunningham K, Dobell R, Fast E, Ferrara N, Findlay CS, Hallstrom LK, Hammond T, Hermanutz L, Hutchings JA, Lindsay KE, Marta TJ, Nguyen VM, Northey G, Prior K, Ramirez-Sanchez S, Rice J, Sleep DJ, Szabo ND, Trottier G, Toussaint JP, Veilleux JP.

Conserv Biol. 2011 Jun;25(3):476-84. doi: 10.1111/j.1523-1739.2010.01625.x. Epub 2010 Dec 22.

27.

High-level production of animal-free recombinant transferrin from Saccharomyces cerevisiae.

Finnis CJ, Payne T, Hay J, Dodsworth N, Wilkinson D, Morton P, Saxton MJ, Tooth DJ, Evans RW, Goldenberg H, Scheiber-Mojdehkar B, Ternes N, Sleep D.

Microb Cell Fact. 2010 Nov 17;9:87. doi: 10.1186/1475-2859-9-87.

28.

Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.

Jones PH, Goldberg AC, Knapp HR, Kelly MT, Setze CM, Stolzenbach JC, Sleep DJ.

Am Heart J. 2010 Oct;160(4):759-66. doi: 10.1016/j.ahj.2010.06.045.

PMID:
20934572
29.

Hydrology and water quality of the headwaters of the River Severn: Stream acidity recovery and interactions with plantation forestry under an improving pollution climate.

Neal C, Robinson M, Reynolds B, Neal M, Rowland P, Grant S, Norris D, Williams B, Sleep D, Lawlor A.

Sci Total Environ. 2010 Oct 1;408(21):5035-51. doi: 10.1016/j.scitotenv.2010.07.047. Epub 2010 Aug 13.

PMID:
20708776
30.

The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.

Bays HE, Roth EM, McKenney JM, Kelly MT, Thakker KM, Setze CM, Obermeyer K, Sleep DJ.

Diabetes Care. 2010 Sep;33(9):2113-6. doi: 10.2337/dc10-0357. Epub 2010 Jun 23.

31.

The production, characterisation and enhanced pharmacokinetics of scFv-albumin fusions expressed in Saccharomyces cerevisiae.

Evans L, Hughes M, Waters J, Cameron J, Dodsworth N, Tooth D, Greenfield A, Sleep D.

Protein Expr Purif. 2010 Oct;73(2):113-24. doi: 10.1016/j.pep.2010.05.009. Epub 2010 May 27.

PMID:
20546898
32.

Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans.

Zhu T, Ansquer JC, Kelly MT, Sleep DJ, Pradhan RS.

J Clin Pharmacol. 2010 Aug;50(8):914-21. doi: 10.1177/0091270009354995. Epub 2010 Feb 9.

PMID:
20145261
33.

Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.

Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC.

Am J Cardiovasc Drugs. 2010;10(2):73-84. doi: 10.2165/10061630-000000000-00000.

PMID:
20136164
34.

Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.

Kipnes MS, Roth EM, Rhyne JM, Setze CM, Lele A, Kelly MT, Sleep DJ, Stolzenbach JC.

Clin Drug Investig. 2010;30(1):51-61. doi: 10.2165/11319800-000000000-00000.

PMID:
19995098
35.

Structures of native human thymidine phosphorylase and in complex with 5-iodouracil.

Mitsiki E, Papageorgiou AC, Iyer S, Thiyagarajan N, Prior SH, Sleep D, Finnis C, Acharya KR.

Biochem Biophys Res Commun. 2009 Sep 4;386(4):666-70. doi: 10.1016/j.bbrc.2009.06.104. Epub 2009 Jun 23.

36.

Structure, properties, and engineering of the major zinc binding site on human albumin.

Blindauer CA, Harvey I, Bunyan KE, Stewart AJ, Sleep D, Harrison DJ, Berezenko S, Sadler PJ.

J Biol Chem. 2009 Aug 21;284(34):23116-24. doi: 10.1074/jbc.M109.003459. Epub 2009 Jun 11.

37.

Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies.

Jones PH, Davidson MH, Goldberg AC, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Lele A, Sleep DJ, Stolzenbach JC.

J Clin Lipidol. 2009 Apr;3(2):125-37. doi: 10.1016/j.jacl.2009.02.007. Epub 2009 Feb 11.

PMID:
21291802
38.

Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.

Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.

Am J Cardiol. 2009 Feb 15;103(4):515-22. doi: 10.1016/j.amjcard.2008.10.025. Epub 2008 Dec 26.

PMID:
19195513
39.

Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.

Mohiuddin SM, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.

Am Heart J. 2009 Jan;157(1):195-203. doi: 10.1016/j.ahj.2008.08.027. Epub 2008 Nov 20.

PMID:
19081418
40.

Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia.

Bays HE, Jones PH, Mohiuddin SM, Kelly MT, Sun H, Setze CM, Buttler SM, Sleep DJ, Stolzenbach JC.

J Clin Lipidol. 2008 Dec;2(6):426-35. doi: 10.1016/j.jacl.2008.10.001. Epub 2008 Nov 12.

PMID:
21291776
41.

Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.

Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.

Atherosclerosis. 2009 May;204(1):208-15. doi: 10.1016/j.atherosclerosis.2008.09.027. Epub 2008 Oct 5.

PMID:
18996523
42.

ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans.

Zhu T, Awni WM, Hosmane B, Kelly MT, Sleep DJ, Stolzenbach JC, Wan K, Chira TO, Pradhan RS.

J Clin Pharmacol. 2009 Jan;49(1):63-71. doi: 10.1177/0091270008325671. Epub 2008 Oct 24.

PMID:
18952910
43.

Modulation of chaperone gene expression in mutagenized Saccharomyces cerevisiae strains developed for recombinant human albumin production results in increased production of multiple heterologous proteins.

Payne T, Finnis C, Evans LR, Mead DJ, Avery SV, Archer DB, Sleep D.

Appl Environ Microbiol. 2008 Dec;74(24):7759-66. doi: 10.1128/AEM.01178-08. Epub 2008 Oct 17.

44.

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.

Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, Petros W, Yenser S, Gockerman JP, Sleep D, Hurwitz H, George DJ.

Clin Cancer Res. 2008 Oct 1;14(19):6270-6. doi: 10.1158/1078-0432.CCR-08-1085.

45.

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.

Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, Qian J, Steinberg J, Carducci M; Atrasentan Phase 3 Study Group.

Cancer. 2008 Nov 1;113(9):2478-87. doi: 10.1002/cncr.23864.

46.

Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.

Jones PH, Bays HE, Davidson MH, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.

Clin Drug Investig. 2008;28(10):625-34.

PMID:
18783301
47.

Single-molecule level analysis of the subunit composition of the T cell receptor on live T cells.

James JR, White SS, Clarke RW, Johansen AM, Dunne PD, Sleep DL, Fitzgerald WJ, Davis SJ, Klenerman D.

Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17662-7. Epub 2007 Oct 30.

48.

Comment arising from a paper by Wittmer et al.: hypothesis testing for top-down and bottom-up effects in woodland caribou population dynamics.

Brown GS, Landriault L, Sleep DJ, Mallory FF.

Oecologia. 2007 Dec;154(3):485-92. Epub 2007 Sep 22. Erratum in: Oecologia. 2007 Dec;154(3):623.

PMID:
17891419
49.
50.

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD, Nelson JB; Atrasentan Phase III Study Group Institutions.

Cancer. 2007 Nov 1;110(9):1959-66.

Supplemental Content

Support Center